COMMUNIQUÉS West-GlobeNewswire

CORRECTING and REPLACING - Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
05/04/2018
In a release issued under the same headline earlier today by Precision Therapeautics (NASDAQ: AIPT ), please note that the forward-looking statements paragraph was missing. The corrected release follows: MINNEAPOLIS, [...]
Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18
04/04/2018
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) ("Sorrento"), announced today that it will present at the H.C. Wainwright Global Lifesciences conference on 04/09/18 at 4:15 PM [...]
Align Technology Extends Invisalign G5 Precision Bite Ramps to Vivera Retainers
04/04/2018
First Customizable Retainers Designed to Help Preserve Beautiful Smiles After Deep Bite Correction with Invisalign Treatment SAN JOSE, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN ) [...]
Align Technology Introduces Invisalign Clear Aligners for Phase 1 Treatment of Younger Patients With Early Mixed Dentition
04/04/2018
Invisalign® First Increases Invisalign Applicability to 70 Percent of Annual Orthodontic Case Starts Worldwide SAN JOSE, Calif., April 04, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (NASDAQ: ALGN ) today announced [...]
Align Technology Expands Invisalign® Product Portfolio With New Options and Greater Flexibility to Treat a Broader Range of Patients
04/04/2018
Creates New Invisalign Treatment Packages to Give Doctors More Choices Extends Popular Teen Features Across the Invisalign Portfolio Launches Clear Aligner Product for Phase 1 Treatment of Young Patients SAN JOSE, Calif [...]
T2 Biosystems Reports Granting of Inducement Awards
04/04/2018
LEXINGTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in [...]
Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial
04/04/2018
Biopsy-based Proof of Concept in Liver Fibrosis and Cirrhosis Supports Further Evaluation Conference Call and Webcast Presentation at 4:30 p.m. ET Today SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Conatus [...]
Immunovaccine Files Circular for Annual and Special Meeting of Shareholders
04/04/2018
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 04, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX: IMV ) (OTCQX:IMMVF), a clinical stage immuno-oncology [...]
Intercept Pharmaceuticals Announces Proposed $120 Million Public Offering and Concurrent $92 Million Private Placement of Common Stock
04/04/2018
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
04/04/2018
-- PDUFA Action Date in October 2018 -- BOSTON, April 04, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK ) announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug [...]
Collegium to Present at the H.C. Wainwright Global Life Sciences Conference
04/04/2018
CANTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL ) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, [...]
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
04/04/2018
ZUG, Switzerland and CAMBRIDGE, MA., April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, [...]
Apricus Biosciences Announces Closing of $3.55 Million Public Offering
04/04/2018
SAN DIEGO, April 04, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the closing of its [...]
Bradmer Announces Fourth Quarter and Full Year 2017 Financial Results
04/04/2018
TORONTO, April 04, 2018 (GLOBE NEWSWIRE) -- Bradmer Pharmaceuticals Inc. (TSX VENTURE:BMR.H) (“Bradmer” or the “Company”) today announced its fourth quarter and full year 2017 financial results. Financial Results [...]
CMS Changes to Medicare Part D Provide Potential Expansion of TRHC Medication Therapy Management Services for Medicare Advantage Plans
04/04/2018
Patient Care vs. Administrative Costs Now the Focus of Part D Health Plan Expenditure Ratios MOORESTOWN, N.J., April 04, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc . (TRHC) (NASDAQ: TRHC ), a healthcare [...]
Legacy Good Samaritan Medical Center in Portland Now Offers Non-Invasive HIFU for Prostate Cancer
04/04/2018
HIFU, high intensity focused ultrasound, is an outpatient procedure for killing prostate tissue in patients with localized prostate cancer and has less risk of side effects than surgery or radiation CHARLOTTE, N.C., [...]
Bone Therapeutics SA : Transparency notification received from S.R.I.W. SA and Sofipôle SA
04/04/2018
Regulated information Transparency notification received from S.R.I.W. SA and Sofipôle SA Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings Gosselies, Belgium, 4 April 2018, 6 pm CEST [...]
Bone Therapeutics SA : Notification de transparence reçue de la part de S.R.I.W. SA et Sofipôle SA
04/04/2018
Information réglementée Notification de transparence reçue de la part de S.R.I.W. SA et Sofipôle SA Article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes Gosselies, [...]
Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
04/04/2018
Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license and collaboration agreement in immuno-oncology to develop OSE-172, a novel checkpoint inhibitor antibody targeting myeloid lineage cells [...]

Pages